BRIEF-Mesoblast provides data from mid-stage trial on cell therapy MPC-300-IV

* Announced 39-week data from phase 2 trial in patients with rheumatoid arthritis resistant to anti-tumor necrosis factor agents
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.